Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients

Thrombosis Research

Volumn 134, Issue 1, 2014, Pages 72-77

  Mizobe, Michio ^a   Hokimoto, Seiji ^a   Akasaka, Tomonori ^a   Arima, Yuichiro ^a   Kaikita, Koichi ^a   Morita, Kazunori ^b   Miyazaki, Hiroko ^b   Oniki, Kentaro ^b   Nakagawa, Kazuko ^b   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Coronary artery disease; Diabetes mellitus; Genomics; Pharmacology; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; HYPERTENSION; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PLATELET REACTIVITY; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENZYMOLOGY; GENETICS; PROSPECTIVE STUDY; STENT; THROMBOCYTE AGGREGATION;

AGED; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP2C19; DIABETES MELLITUS; FEMALE; GENOTYPE; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; STENTS; TICLOPIDINE;

EID: 84902554010     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.04.020     Document Type: Article

References (32)

1. S.B. King III, S.C. Smith Jr., J.W. Hirshfeld Jr., A.K. Jacobs, D.A. Morrison, and D.O. Williams et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines J Am Coll Cardiol 51 2008 172 209
2. F.G. Kushner, M. Hand, S.C. Smith Jr., S.B. King III, J.L. Anderson, and E.M. Antman et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
3. R.S. Wright, J.L. Anderson, C.D. Adams, C.R. Bridges, D.E. Casey Jr., and S.M. Ettinger et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 57 2011 1920 1959
4. Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, and R. Peto et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
5. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendon, G. Montalescot, and P. Theroux et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
6. L. Ang, V. Palakodeti, A. Khalid, S. Tsimikas, Z. Idrees, and P. Tran et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel J Am Coll Cardiol 52 2008 1052 1059
7. T. Geisler, D. Grass, B. Bigalke, K. Stellos, T. Drosch, and K. Dietz et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score J Thromb Haemost 6 2008 54 61
8. K. Yamamoto, S. Hokimoto, T. Chitose, K. Morita, T. Ono, and K. Kaikita et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy J Cardiol 57 2011 194 201
9. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt et al. Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
10. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Meneveau et al. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
11. V. Serebruany, G. Cherala, C. Williams, S. Surigin, C. Booze, and W. Kuliczkowski et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance" Am Heart J 158 2009 925 932
12. T. Geisler, C. Zurn, R. Simonenko, M. Rapin, H. Kraibooj, and A. Kilias et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions Eur Heart J 31 2010 59 66
13. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, and J. Silvain et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
14. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina et al. Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
15. S.S. Sethi, E.G. Akl, and M.E. Farkouh Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials Curr Diab Rep 12 2012 294 304
16. K. Sakata, K. Waseda, T. Kume, H. Otake, D. Nakatani, and P.G. Yock et al. Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses Circ Cardiovasc Interv 5 2012 763 771
17. C. Andersson, S. Lyngbaek, C.D. Nguyen, M. Nielsen, G.H. Gislason, and L. Kober et al. Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes JAMA 308 2012 882 889
18. M. Man, M. Farmen, C. Dumaual, C.H. Teng, B. Moser, and S. Irie et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans J Clin Pharmacol 50 2010 929 940
19. B. Richards, J. Skoletsky, A.P. Shuber, R. Balfour, R.C. Stern, and H.L. Dorkin et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs Hum Mol Genet 2 1993 159 163
20. T. Kubota, K. Chiba, and T. Ishizaki Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population Clin Pharmacol Ther 60 1996 661 666
21. S.M. De Morais, G.R. Wilkinson, J. Blaisdell, U.A. Meyer, K. Nakamura, and J.A. Goldstein Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 1994 594 598
22. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Beinart, and I. Goldenberg et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
23. W.M. Samara, K.P. Bliden, U.S. Tantry, and P.A. Gurbel The difference between clopidogrel responsiveness and posttreatment platelet reactivity Thromb Res 115 2005 89 94
24. T. Ono, K. Kaikita, S. Hokimoto, S. Iwashita, K. Yamamoto, and Y. Miyazaki et al. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention Thromb Res 128 2011 e130 e136
25. K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, and H.D. White Third Universal Definition of Myocardial Infarction Circulation 126 2012 2020 2035
26. M.B. McEntegart, A.J. Kirtane, E. Cristea, S. Brener, R. Mehran, and M. Fahy et al. Intraprocedural thrombotic events during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes are associated with adverse outcomes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J Am Coll Cardiol 59 2012 1745 1751
27. G.W. Stone, A. Abizaid, S. Silber, J.M. Dizon, B. Merkely, and R.A. Costa et al. Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial. J Am Coll Cardiol 60 2012 1975 1984
28. G.W. Stone, B. Witzenbichler, G. Weisz, M.J. Rinaldi, F.J. Neumann, and D.C. Metzger et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
29. T. Sato, T. Ono, Y. Morimoto, H. Kawai, S. Fuke, and T. Ikeda et al. Differences in clinical and angiographic outcomes with different drug-eluting stents in Japanese patients with and without diabetes mellitus J Cardiol 60 2012 361 366
30. S. Elezi, A. Kastrati, J. Pache, A. Wehinger, M. Hadamitzky, and J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement J Am Coll Cardiol 32 1998 1866 1873
31. E. Van Belle, M. Perie, D. Braune, A. Chmait, T. Meurice, and K et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients J Am Coll Cardiol 40 2002 410 417
32. SM. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234